Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zentius Flash
- Development stage
- Phase 4
- Lead developer
- ITF Ilaç San. ve Tic. Ltd. Şti.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zentius Flash is an orally disintegrating tablet (ODT) combination therapy containing 600 mg of calcium carbonate and 400 I.U. of vitamin D3 (cholecalciferol). Developed and marketed by ITF İlaç Sanayi ve Ticaret in Turkey and manufactured by Italfarmaco S.p.A. in Italy, it is indicated for the prevention and treatment of calcium and vitamin D deficiencies, as well as an adjunct in the management of osteoporosis. The ODT formulation is designed to dissolve quickly in the mouth without the need for water, facilitating ease of use and potentially improving patient adherence in populations with swallowing difficulties. It is regulated as a prescription medication (Beyaz Reçete) in Turkey.
- Brand names
- Zentius Flash
Beyond the preview
Go deeper on Zentius Flash.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zentius Flash.